216 related articles for article (PubMed ID: 37041967)
1. Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry.
Salmanton-García J; Marchesi F; Gomes da Silva M; Farina F; Dávila-Valls J; Bilgin YM; Glenthøj A; Falces-Romero I; Van Doesum J; Labrador J; Buquicchio C; El-Ashwah S; Petzer V; Van Praet J; Schönlein M; Dargenio M; Méndez GA; Meers S; Itri F; Giordano A; Pinczés LI; Espigado I; Stojanoski Z; López-García A; Prezioso L; Jaksic O; Vena A; Fracchiolla NS; González-López TJ; Colović N; Delia M; Weinbergerová B; Marchetti M; Marques de Almeida J; Finizio O; Besson C; Biernat MM; Valković T; Lahmer T; Cuccaro A; Ormazabal-Vélez I; Batinić J; Fernández N; De Jonge N; Tascini C; Anastasopoulou AN; Duléry R; Del Principe MI; Plantefeve G; Papa MV; Nucci M; Jiménez M; Aujayeb A; Hernández-Rivas JÁ; Merelli M; Cattaneo C; Blennow O; Nordlander A; Cabirta A; Varricchio G; Sacchi MV; Cordoba R; Arellano E; Gräfe SK; Wolf D; Emarah Z; Ammatuna E; Hersby DS; Martín-Pérez S; Nunes Rodrigues R; Rahimli L; Pagano L; Cornely OA;
EClinicalMedicine; 2023 Apr; 58():101939. PubMed ID: 37041967
[TBL] [Abstract][Full Text] [Related]
2. Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registry.
Salmanton-García J; Marchesi F; Koehler P; Weinbergerová B; Čolović N; Falces-Romero I; Buquicchio C; Farina F; van Praet J; Biernat MM; Itri F; Prezioso L; Tascini C; Vena A; Romano A; Delia M; Dávila-Valls J; Martín-Pérez S; Lavilla-Rubira E; Adžić-Vukičević T; García-Bordallo D; López-García A; Criscuolo M; Petzer V; Fracchiolla NS; Espigado I; Sili U; Meers S; Erben N; Cattaneo C; Tragiannidis A; Gavriilaki E; Schönlein M; Mitrovic M; Pantic N; Merelli M; Labrador J; Hernández-Rivas JÁ; Glenthøj A; Fouquet G; Del Principe MI; Dargenio M; Calbacho M; Besson C; Kohn M; Gräfe S; Hersby DS; Arellano E; Çolak GM; Wolf D; Marchetti M; Nordlander A; Blennow O; Cordoba R; Mišković B; Mladenović M; Bavastro M; Limongelli A; Rahimli L; Pagano L; Cornely OA
Int J Antimicrob Agents; 2023 Oct; 62(4):106952. PubMed ID: 37582478
[TBL] [Abstract][Full Text] [Related]
3. Real-life comparison of mortality in patients with SARS-CoV-2 infection at risk for clinical progression treated with molnupiravir or nirmatrelvir plus ritonavir during the Omicron era in Italy: a nationwide, cohort study.
Torti C; Olimpieri PP; Bonfanti P; Tascini C; Celant S; Tacconi D; Nicastri E; Tacconelli E; Cacopardo B; Perrella A; Buccoliero GB; Parruti G; Bassetti M; Biagetti C; Giacometti A; Erne EM; Frontuto M; Lanzafame M; Summa V; Spagnoli A; Vestri A; Di Perri G; Russo P; Palù G
Lancet Reg Health Eur; 2023 Aug; 31():100684. PubMed ID: 37547273
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of molnupiravir vs nirmatrelvir-ritonavir in non-hospitalised and hospitalised patients with COVID-19: a target trial emulation study.
Wan EYF; Yan VKC; Wong ZCT; Chui CSL; Lai FTT; Li X; Wong CKH; Hung IFN; Lau CS; Wong ICK; Chan EWY
EClinicalMedicine; 2023 Oct; 64():102225. PubMed ID: 37753272
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of nirmatrelvir-ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system.
Lewnard JA; McLaughlin JM; Malden D; Hong V; Puzniak L; Ackerson BK; Lewin BJ; Kim JS; Shaw SF; Takhar H; Jodar L; Tartof SY
Lancet Infect Dis; 2023 Jul; 23(7):806-815. PubMed ID: 36933565
[TBL] [Abstract][Full Text] [Related]
6. Antiviral effectiveness and survival correlation of azvudine and nirmatrelvir/ritonavir in elderly severe patients with COVID-19: a retrospective real-world study.
Wang S; Sun J; Zhang X; Li M; Qin B; Liu M; Zhang N; Wang S; Zhou T; Zhang W; Ma C; Deng X; Bai Y; Qu G; Liu L; Shi H; Zhou B; Li K; Yang B; Li S; Wang F; Ma J; Zhang L; Wang Y; An L; Liu W; Chang Q; Zhang R; Yin X; Yang Y; Ao Q; Ma Q; Yan S; Huang H; Song P; Gao L; Lu W; Xu L; Lei L; Wang K; Zhang Q; Song Q; Zhang Z; Fang X; He Y; Li T; Zhu P
EClinicalMedicine; 2024 Mar; 69():102468. PubMed ID: 38361990
[TBL] [Abstract][Full Text] [Related]
7. Real-world effectiveness of nirmatrelvir/ritonavir against COVID-19 hospitalizations and severe COVID-19 in community-dwelling elderly Singaporeans during Omicron BA.2, BA.4/5, and XBB transmission.
Wee LE; Tay AT; Chiew C; Young BE; Wong B; Lim R; Lee CL; Tan J; Vasoo S; Lye DC; Tan KB
Clin Microbiol Infect; 2023 Oct; 29(10):1328-1333. PubMed ID: 37331509
[TBL] [Abstract][Full Text] [Related]
8. Remdesivir or Nirmatrelvir/Ritonavir Therapy for Omicron SARS-CoV-2 Infection in Hematological Patients and Cell Therapy Recipients.
Piñana JL; Heras I; Aiello TF; García-Cadenas I; Vazquez L; Lopez-Jimenez J; Chorão P; Aroca C; García-Vidal C; Arroyo I; Soler-Espejo E; López-Corral L; Avendaño-Pita A; Arrufat A; Garcia-Gutierrez V; Arellano E; Hernández-Medina L; González-Santillana C; Morell J; Hernández-Rivas JÁ; Rodriguez-Galvez P; Mico-Cerdá M; Guerreiro M; Campos D; Navarro D; Cedillo Á; Martino R; Solano C;
Viruses; 2023 Oct; 15(10):. PubMed ID: 37896843
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of nirmatrelvir-ritonavir against hospital admission or death: a cohort study in a large US healthcare system.
Lewnard JA; McLaughlin JM; Malden D; Hong V; Puzniak L; Ackerson BK; Lewin BJ; Kim JS; Shaw SF; Takhar H; Jodar L; Tartof SY
medRxiv; 2023 Jan; ():. PubMed ID: 36238720
[TBL] [Abstract][Full Text] [Related]
10. Real-World Effectiveness of Nirmatrelvir/Ritonavir on Coronavirus Disease 2019-Associated Hospitalization Prevention: A Population-based Cohort Study in the Province of Quebec, Canada.
Kaboré JL; Laffont B; Diop M; Tardif MR; Turgeon AF; Dumaresq J; Luong ML; Cauchon M; Chapdelaine H; Claveau D; Brosseau M; Haddad E; Benigeri M
Clin Infect Dis; 2023 Sep; 77(6):805-815. PubMed ID: 37149726
[TBL] [Abstract][Full Text] [Related]
11. Nirmatrelvir/Ritonavir Utilization for the Treatment of Non-hospitalized Adults with COVID-19 in the National Veterans Affairs (VA) Healthcare System.
Appaneal HJ; LaPlante KL; Lopes VV; Martin C; Puzniak L; Wiemken TL; Zasowski EJ; McLaughlin JM; Caffrey AR
Infect Dis Ther; 2024 Jan; 13(1):155-172. PubMed ID: 38217842
[TBL] [Abstract][Full Text] [Related]
12. Real-World Effectiveness of Nirmatrelvir-Ritonavir and Its Acceptability in High-Risk COVID-19 Patients.
Kim MK; Lee KS; Ham SY; Choi YY; Lee E; Lee S; Lee B; Jeon J; Chin B; Kim Y; Kim G; Jang HC; Choi JP; Park SW
J Korean Med Sci; 2023 Sep; 38(35):e272. PubMed ID: 37667578
[TBL] [Abstract][Full Text] [Related]
13. Association of Nirmatrelvir/Ritonavir Treatment on Upper Respiratory Severe Acute Respiratory Syndrome Coronavirus 2 Reverse Transcription-Polymerase Chain Reaction (SARS-Cov-2 RT-PCR) Negative Conversion Rates Among High-Risk Patients With Coronavirus Disease 2019 (COVID-19).
Li H; Gao M; You H; Zhang P; Pan Y; Li N; Qin L; Wang H; Li D; Li Y; Qiao H; Gu L; Xu S; Guo W; Wang N; Liu C; Gao P; Niu J; Cao J; Zheng Y
Clin Infect Dis; 2023 Feb; 76(3):e148-e154. PubMed ID: 35870128
[TBL] [Abstract][Full Text] [Related]
14. The effect of nirmatrelvir-ritonavir on viral clearance and length of hospital stay in patients infected with SARS-CoV-2 omicron variants.
Wang Y; Zhao D; Chen X; Liu X; Xiao W; Feng L
Influenza Other Respir Viruses; 2023 Feb; 17(2):e13095. PubMed ID: 36843224
[TBL] [Abstract][Full Text] [Related]
15. Nirmatrelvir/ritonavir and risk of long COVID symptoms: a retrospective cohort study.
Congdon S; Narrowe Z; Yone N; Gunn J; Deng Y; Nori P; Cowman K; Islam M; Rikin S; Starrels J
Sci Rep; 2023 Nov; 13(1):19688. PubMed ID: 37951998
[TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness of nirmatrelvir/ritonavir versus sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in non-hospitalised high-risk patients during Omicron waves: observational cohort study using the OpenSAFELY platform.
Zheng B; Tazare J; Nab L; Green AC; Curtis HJ; Mahalingasivam V; Herrett EL; Costello RE; Eggo RM; Speed V; Bacon SC; Bates C; Parry J; Cockburn J; Hester F; Harper S; Schaffer AL; Hulme WJ; Mehrkar A; Evans SJ; MacKenna B; Goldacre B; Douglas IJ; Tomlinson LA;
Lancet Reg Health Eur; 2023 Nov; 34():100741. PubMed ID: 37927438
[TBL] [Abstract][Full Text] [Related]
17. Nirmatrelvir/ritonavir treatment in SARS-CoV-2 positive kidney transplant recipients - a case series with four patients.
Schneider J; Wobser R; Kühn W; Wagner D; Tanriver Y; Walz G
BMC Nephrol; 2023 Apr; 24(1):99. PubMed ID: 37061677
[TBL] [Abstract][Full Text] [Related]
18. Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large U.S. Health System : A Population-Based Cohort Study.
Dryden-Peterson S; Kim A; Kim AY; Caniglia EC; Lennes IT; Patel R; Gainer L; Dutton L; Donahue E; Gandhi RT; Baden LR; Woolley AE
Ann Intern Med; 2023 Jan; 176(1):77-84. PubMed ID: 36508742
[TBL] [Abstract][Full Text] [Related]
19. Population-based evaluation of the effectiveness of nirmatrelvir-ritonavir for reducing hospital admissions and mortality from COVID-19.
Schwartz KL; Wang J; Tadrous M; Langford BJ; Daneman N; Leung V; Gomes T; Friedman L; Daley P; Brown KA
CMAJ; 2023 Feb; 195(6):E220-E226. PubMed ID: 36781188
[TBL] [Abstract][Full Text] [Related]
20. Is Azvudine Comparable to Nirmatrelvir-Ritonavir in Real-World Efficacy and Safety for Hospitalized Patients with COVID-19? A Retrospective Cohort Study.
Zhao Q; Zheng B; Han B; Feng P; Xia Z; Jiang H; Ying Y; Zhu J; Fei C; Xiang J; Shen L; Luo Q; Wu Y; Wusiman A; Xin C; Zhang M; Li G; Li X
Infect Dis Ther; 2023 Aug; 12(8):2087-2102. PubMed ID: 37486556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
